论文部分内容阅读
目的观察静脉溶栓治疗急性脑梗死的疗效。方法选取2013年7月~2015年7月我院收治的急性脑梗死患者68例作为研究对象,将其随机分为研究组和对照组,各34例。研究组采用重组组织型的纤溶酶原激活物rt PA(爱通立)静脉滴注,对照组采低分子右旋糖酐另加复方丹参静脉滴注,并对比两组患者的疗效。结果经过24 h和21天的治疗后,研究组的ESS评分结果均优于对照组的,且差异有统计学意义(P<0.05);经过3个月的治疗后,研究组的治疗总有效率为91.18%,远高于对照组的67.65%,且差异有统计学意义(P<0.05)。结论将重组组织型的纤溶酶原激活物rt PA(爱通立)静脉滴注溶栓应用于急性脑梗死的临床治疗上,可获得较为理想的应用疗效,并有效提升患者的临床治愈率,值得推广。
Objective To observe the curative effect of intravenous thrombolysis on acute cerebral infarction. Methods Seventy-six patients with acute cerebral infarction admitted to our hospital from July 2013 to July 2015 were selected as study subjects and randomly divided into study group and control group, with 34 cases in each group. The study group used recombinant tissue-type plasminogen activator rt PA (Aitongli) intravenous drip, the control group was taken low molecular dextran plus compound Salvia intravenous drip, and compared the efficacy of two groups of patients. Results After 24 and 21 days of treatment, the ESS score of the study group was better than that of the control group (P <0.05). After 3 months of treatment, the treatment group had a total of The efficiency was 91.18%, much higher than 67.65% of the control group, and the difference was statistically significant (P <0.05). Conclusion The recombinant tissue-type plasminogen activator rt PA (Aitongli) intravenous infusion of thrombolysis in the clinical treatment of acute cerebral infarction, can be more ideal for the application of efficacy, and effectively improve the clinical cure rate , Worth promoting.